Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Treasury Shares (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Treasury Shares for 7 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 57.93% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, up 57.93% year-over-year, with the annual reading at $2.9 million for FY2025, 57.93% up from the prior year.
  • Treasury Shares for Q4 2025 was $2.9 million at Rhythm Pharmaceuticals, up from $1.8 million in the prior quarter.
  • The five-year high for Treasury Shares was $2.9 million in Q4 2025, with the low at $804797.0 in Q4 2022.
  • Average Treasury Shares over 5 years is $1.5 million, with a median of $1.1 million recorded in 2023.
  • The sharpest move saw Treasury Shares decreased 15.83% in 2022, then surged 65.37% in 2024.
  • Over 5 years, Treasury Shares stood at $956145.0 in 2021, then dropped by 15.83% to $804797.0 in 2022, then soared by 37.25% to $1.1 million in 2023, then soared by 65.37% to $1.8 million in 2024, then surged by 57.93% to $2.9 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $2.9 million, $1.8 million, and $1.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.